Evaluating pain relief from a nerve block during hip replacement surgery
The Analgesic Efficacy of Pericapsular Nerve Group (PENG) Block in Patients Undergoing Primary Total Hip Arthoplasty: a Prospective, Double-blinded, Randomized Controlled Trial
This study is testing if a special nerve block can help reduce pain after hip replacement surgery by comparing it to a placebo.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 110 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Diakonie-Klinikum Stuttgart Academic / other |
| Locations | 1 site (Stuttgart, Baden-Wurttemberg) |
| Trial ID | NCT06557044 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of the pericapsular nerve group (PENG) block in providing analgesia for patients undergoing primary total hip arthroplasty. Participants are randomly assigned to receive either 20 ml of ropivacaine or a placebo saline solution during their surgery. The study is designed to be prospective and double-blind, ensuring unbiased results regarding pain management. The goal is to determine if the PENG block can significantly reduce postoperative pain compared to standard care.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 scheduled for a cementless hip replacement due to primary osteoarthritis.
Not a fit: Patients with chronic pain conditions, previous hip surgeries, or contraindications to the study medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved pain management and recovery for patients undergoing hip replacement surgery.
How similar studies have performed: Previous studies have shown promising results with nerve blocks for pain management in orthopedic surgeries, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * planned cementless hip TEP operation for primary coxarthrosis via minimally invasive anterolateral approach using the identical implant system (Taperloc stem, Plamafit cup) * Patient capable of giving consent * Informed consent has been obtained * age \> 18 years Exclusion Criteria: * Refusal to participate in the study * Regular use of opioids * Known chronic pain symptoms * Infections in the area of the puncture site * Presence of a contraindication to ropivacaine * Presence of a contraindication to metamizole * Presence of a contraindication to postoperative analgesia with diclofenac * Secondary forms of osteoarthritis with deformities (i.e. high-grade dysplasia, secondary conditions after trauma, secondary conditions after childtrauma, secondary conditions after childhood hip joint diseases * Spinopelvic dysbalance, spinal canal stenosis * Previous operations on the hip/pelvis
Where this trial is running
Stuttgart, Baden-Wurttemberg
- Diakonie-Klinikum Stuttgart — Stuttgart, Baden-Wurttemberg, Germany (Recruiting)
Study contacts
- Study coordinator: Rainer Meierhenrich, Prof. Dr.
- Email: meierhenrich@diak-stuttgart.de
- Phone: 00497119912290
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.